NxStage Medical, Inc. (NXTM) Expected to Announce Earnings of -$0.02 Per Share

Share on StockTwits

Brokerages predict that NxStage Medical, Inc. (NASDAQ:NXTM) will post earnings of ($0.02) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for NxStage Medical’s earnings. The lowest EPS estimate is ($0.05) and the highest is $0.02. NxStage Medical posted earnings of ($0.14) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 85.7%. The business is expected to issue its next quarterly earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that NxStage Medical will report full-year earnings of ($0.02) per share for the current year, with EPS estimates ranging from ($0.15) to $0.13. For the next fiscal year, analysts anticipate that the company will post earnings of $0.09 per share, with EPS estimates ranging from ($0.05) to $0.25. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $106.97 million during the quarter, compared to analyst estimates of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.

A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.

NxStage Medical stock traded down $0.05 during midday trading on Friday, reaching $28.98. 314,702 shares of the stock traded hands, compared to its average volume of 654,908. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -131.73 and a beta of -0.05. NxStage Medical has a fifty-two week low of $22.70 and a fifty-two week high of $29.19.

Large investors have recently modified their holdings of the company. NumerixS Investment Technologies Inc acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $122,000. Steward Partners Investment Advisory LLC lifted its stake in shares of NxStage Medical by 714.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after acquiring an additional 5,000 shares during the period. Keybank National Association OH acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $212,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $216,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $234,000. 83.15% of the stock is owned by institutional investors.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Featured Story: What is insider trading?

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply